



**Australian Government**  
**Repatriation Medical Authority**

**Amendment Statement of Principles**  
**concerning**  
**HYPOGONADISM**  
**(Reasonable Hypothesis)**  
**(No. 51 of 2022)**

---

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 29 April 2022

The Common Seal of the  
Repatriation Medical Authority  
was affixed to this instrument  
at the direction of:

Professor Terence Campbell AM  
Chairperson

# Contents

1	Name.....	3
2	Commencement.....	3
3	Authority.....	3
4	Amendment.....	3

**1 Name**

This is the Amendment Statement of Principles concerning *hypogonadism (Reasonable Hypothesis)* (No. 51 of 2022).

**2 Commencement**

This instrument commences on 30 May 2022.

**3 Authority**

This instrument is made under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

**4 Amendment**

The Statement of Principles concerning *hypogonadism (Reasonable Hypothesis)* (No. 73 of 2021) (Federal Register of Legislation No. F2021L00619) is amended in the following manner:

<b>Section</b>	<b>Amendment</b>
<i>Schedule 1 – Dictionary</i>	<i>Replace the existing definition of "immune checkpoint inhibitor" with the following:</i>  <b>immune checkpoint inhibitor</b> means a form of cancer immunotherapy that uses monoclonal antibodies targeting the immune checkpoint proteins. Examples include ipilimumab, tremelimumab, nivolumab and pembrolizumab.